IDEAS home Printed from https://ideas.repec.org/a/nat/nature/v451y2008i7182d10.1038_nature06633.html
   My bibliography  Save this article

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

Author

Listed:
  • Wataru Sakai

    (Division of Human Biology,
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA)

  • Elizabeth M. Swisher

    (Department of Obstetrics and Gynecology,
    University of Washington, Seattle, Washington 98195-7720, USA)

  • Beth Y. Karlan

    (Cedars-Sinai Medical Center, Women’s Cancer Research Institute, Los Angeles, California 90048-1865, USA)

  • Mukesh K. Agarwal

    (Mayo Clinic, Rochester, Minnesota 55905, USA)

  • Jake Higgins

    (University of Washington, Seattle, Washington 98195-7720, USA
    University of Washington, Seattle, Washington 98195-7720, USA)

  • Cynthia Friedman

    (Division of Human Biology,)

  • Emily Villegas

    (Division of Human Biology,
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA)

  • Céline Jacquemont

    (Division of Human Biology,
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA)

  • Daniel J. Farrugia

    (Mayo Clinic, Rochester, Minnesota 55905, USA)

  • Fergus J. Couch

    (Mayo Clinic, Rochester, Minnesota 55905, USA)

  • Nicole Urban

    (Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA)

  • Toshiyasu Taniguchi

    (Division of Human Biology,
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA)

Abstract

Resistance in BRCA2 cancers The platinum chemotherapeutics such as cisplatin and carboplatin are in clinical use in patients with BRCA2-mutated ovarian cancer. The initial response is generally good but most ovarian carcinomas ultimately become resistant to therapy. Two papers in this issue have identified a possible cause of this resistance as further mutation of the BRCA2 gene. Mutations in BRCA2 are associated with familial breast and ovarian cancer. Loss of BRCA2 function impairs DNA repair by homologous recombination and renders cells particular sensitive to cisplatin and also to PARP (poly (ADP-ribose) polymerase) inhibitors. The secondary 'resistance' mutations act by restoring the wild-type BRCA2 reading frame.

Suggested Citation

  • Wataru Sakai & Elizabeth M. Swisher & Beth Y. Karlan & Mukesh K. Agarwal & Jake Higgins & Cynthia Friedman & Emily Villegas & Céline Jacquemont & Daniel J. Farrugia & Fergus J. Couch & Nicole Urban & , 2008. "Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers," Nature, Nature, vol. 451(7182), pages 1116-1120, February.
    • Handle: RePEc:nat:nature:v:451:y:2008:i:7182:d:10.1038_nature06633
    DOI: 10.1038/nature06633
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/nature06633
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1038/nature06633?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Georgia Zoumpoulidou & Carlos Alvarez-Mendoza & Caterina Mancusi & Ritika-Mahmuda Ahmed & Milly Denman & Christopher D. Steele & Maxime Tarabichi & Errin Roy & Lauren R. Davies & Jiten Manji & Camilla, 2021. "Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma," Nature Communications, Nature, vol. 12(1), pages 1-16, December.
    2. Jennifer B. Shah & Dana Pueschl & Bradley Wubbenhorst & Mengyao Fan & John Pluta & Kurt D’Andrea & Anna P. Hubert & Jake S. Shilan & Wenting Zhou & Adam A. Kraya & Alba Llop Guevara & Catherine Ruan &, 2022. "Analysis of matched primary and recurrent BRCA1/2 mutation-associated tumors identifies recurrence-specific drivers," Nature Communications, Nature, vol. 13(1), pages 1-19, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:451:y:2008:i:7182:d:10.1038_nature06633. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.